Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a significant increase in stock price, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Changsheng Fund hold a total of 343,900 shares of Tiger Med, with a floating profit of approximately 873,500 CNY based on the previous day's closing price of 50.78 CNY and the current price of 53.32 CNY [2][8]. - The Changsheng Medical Quantitative Stock A fund holds 180,900 shares, representing 7.23% of the fund's net value, while the Changsheng Pension Health Mixed A fund holds 163,000 shares, representing 7.98% of the fund's net value [3][7].